Arvinas, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARVN research report →
Range $10 – $14
Price Chart
About the company
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates.
- CEO
- Randy Teel
- IPO
- 2018
- Employees
- 246
- HQ
- New Haven, CT, US
Get TickerSpark's AI analysis on ARVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $423.03M
- P/E
- -43.07
- Fwd P/E
- 39.91
- PEG
- 0.93
- P/S
- 1.54
- P/B
- 0.82
- EV/EBITDA
- -15.79
- Div Yield
- 0.00%
- Gross Margin
- 95.86%
- Op Margin
- -10.68%
- Net Margin
- -3.45%
- ROE
- -2.00%
- ROIC
- -5.45%
Latest fiscal year · YoY change
- Revenue
- $262.60M-0.3%
- Gross Profit
- $257.40M-2.3%
- Op Income
- $-114,900,000
- Net Income
- $-80,800,000+59.4%
- EPS
- $-1.28+53.8%
- OCF Growth
- -5.6%
- FCF Growth
- -5.6%
- 52W High
- $14.51
- 52W Low
- $6.33
- 50D MA
- $7.44
- 200D MA
- $9.26
- Beta
- 1.80
- RSI (14)
- 37
- Avg Volume
- 846.07K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arvinas emphasized a data-driven capital-allocation strategy, with multiple clinical readouts ahead and a cash runway into the second half of 2028.· November 3, 2026
- Q3 cash, cash equivalents, restricted cash and marketable securities were $558.9 million, and management said runway extends into the second half of 2028.
- The company booked its first royalty from Rigel in the quarter: $0.5 million, with a Yale royalty of about 1% on royalty revenue.
- R&D fell to $46.9 million from $64.7 million a year ago; G&A fell to $12.6 million from $21 million, helping reduce non-GAAP expenses 25% year over year to $53.5 million.
- ARV-393 remains the near-term catalyst, with initial monotherapy dose-escalation data planned for ASH in December and a second readout expected in mid-2027.
- ARV-102 will now prioritize a phase I-B study in Europe and the U.K. while U.S. discussions with the FDA continue; SBMA and HPK1 data are expected in 2027.
Arvinas reported Q3 2026 results including $0.5 million of royalty revenue from Rigel. General and administrative expense was $12.6 million versus $21 million a year ago, and research and development expense was $46.9 million versus $64.7 million a year ago. Non-GAAP R&D declined 22% year over year, non-GAAP G&A declined 37%, and non-GAAP expenses totaled $53.5 million versus $71.5 million, a 25% reduction. The company ended Q3 with $558.9 million in cash equivalents, restricted cash and marketable securities, and said it has cash into the second half of 2028. Management did not provide quarterly revenue or EPS beyond the $0.5 million royalty, and it did not issue numeric full-year financial guidance; instead, it outlined clinical milestones and funding coverage for ongoing programs.
Randy Teel framed the quarter around disciplined capital allocation and a pipeline approaching multiple catalysts. He said the company will prioritize programs where emerging evidence supports the greatest potential for value creation and reiterated that Arvinas wants to let data drive investment decisions. His tone was confident and forward-looking, especially around ARV-393, ARV-027, ARV-6723 and ARV-102, which he described as examples of protein degradation potentially creating transformational therapies.
Andrew Saik highlighted a stronger cost profile and a substantial cash position. He said cash, cash equivalents, restricted cash and marketable securities were $558.9 million at quarter-end versus $685.4 million at the end of 2025, and that the company’s projected cash extends into the second half of 2028. He cited the first Rigel royalty of $0.5 million, a 1% royalty rate on royalty revenue under the Yale agreement, and lower spending across the business: G&A of $12.6 million, R&D of $46.9 million, and non-GAAP expenses of $53.5 million. He also said the current quarter’s spend is a good representation of what to expect over the next few quarters as early-stage development continues.
Analysts focused heavily on ARV-102, ARV-393, ARV-027 and the Yale royalty. Management said the ARV-102 U.S. clinical hold remains under discussion with the FDA, but the plan is to proceed with a phase I-B study in Europe and the U.K. without U.S. patients for now. On ARV-027, management said the goal is about 50% polyQ-AR reduction, and that healthy-volunteer data are intended to help select a dose before SBMA patient dosing in the first half of 2027; they do not view a specific healthy-volunteer threshold as gating entry into patients. For ARV-393, management said the first ASH disclosure will focus on T-cell lymphoma with mid-teens patient counts and that the mid-2027 update will better reflect B-cell activity, higher doses and initial glofitamab combination data.
The company has enough cash to get through multiple upcoming clinical milestones, and management repeatedly emphasized disciplined spending and careful capital allocation. Early signals across the pipeline sounded encouraging: ARV-393 showed responses even at lower doses, ARV-027 has a clear biologic target and preclinical support, and ARV-102 showed biomarker and oculomotor findings that management views as supportive of further development. Management also pointed to first-in-class opportunities in BCL6, SBMA, HPK1 and LRRK2 degradation.
Several programs still face significant execution and regulatory risk. ARV-102 remains on U.S. clinical hold, so the next step is shifting development to Europe and the U.K., with no clear timeline for U.S. re-entry. ARV-393’s first readout is from low doses with limited durability, so management itself said the ASH data may be early and not yet fully informative for B-cell efficacy. For ARV-027 and ARV-6723, meaningful clinical proof-of-concept is still ahead, and management acknowledged that translation from biomarkers or preclinical models to patient benefit remains to be proven.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.6%
- Shares Outstanding
- 65.48M
- Float Shares
- 58.68M
of shares held by institutions
206 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.25M | ▲ 641.74K |
| Vanguard Group Inc | 7.23M | ▼ 1.33M |
| Vanguard Portfolio Management LLC | 4.18M | ▲ 54.15K |
| D. E. Shaw & Co., Inc. | 3.50M | ▼ 143.41K |
| Pfizer Inc | 3.46M | 0 |
| Armistice Capital, LLC | 2.80M | ▲ 818.00K |
| Vanguard Capital Management LLC | 2.68M | ▼ 38.84K |
| Two Sigma Investments, LP | 2.57M | ▲ 741.33K |
| State Street Corp | 2.08M | ▼ 117.97K |
| Affinity Asset Advisors, LLC | 2.05M | ▲ 2.05M |
| Jacobs Levy Equity Management, Inc | 1.41M | ▼ 28.88K |
| Federated Hermes, Inc. | 1.41M | ▲ 56.53K |
Held by 263 ETFs
Biggest fund positions in ARVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Loomis David K | sell | 232 |
| Jun 24, 26 | Smaldone Alsup Laurie | other | 15,527 |
| Jun 24, 26 | Smaldone Alsup Laurie | other | 22,714 |
| Jun 24, 26 | Norwalk Leslie V | other | 15,527 |
| Jun 24, 26 | Norwalk Leslie V | other | 22,714 |
| Jun 24, 26 | Morrison Briggs | other | 15,527 |
| Jun 24, 26 | Morrison Briggs | other | 22,714 |
| Jun 24, 26 | Kennedy Edward Moore Jr. | other | 15,527 |
| Jun 24, 26 | Kennedy Edward Moore Jr. | other | 22,714 |
| Jun 24, 26 | Cunningham Everett | other | 15,527 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARVN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ARVN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Arvinas to Present at Jefferies Global Healthcare Conference
globenewswire.com · Nov 11
What Arvinas (ARVN) Said on Its Q3 Earnings Call
defenseworld.net · Nov 5
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
globenewswire.com · Nov 4
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
What Arvinas (ARVN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 3
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 3
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
